Literature DB >> 23127500

Increased monoaminergic neurotransmission improves compliance with physical activity recommendations in depressed patients with fatigue.

Emelie Stenman1, Asa Lilja.   

Abstract

Clinical studies have shown that moderately intense physical activity effectively treats various types of depression. Beneficial effects have been reported in the acute phase of the disease as well as in a long-term perspective. In addition, epidemiological studies have shown that inactivity increases the risk of depression and that exercise prevents relapse. Depressed patients are often prescribed antidepressants, with or without psychotherapy. Some studies have, however, suggested that the most frequently used antidepressants, selective serotonin reuptake inhibitors (SSRIs), contribute to fatigue, which is a common residual symptom associated with depression and the target of the proposed study. Profound fatigue may in turn decrease the ability and motivation to perform the beneficial physical activity, e.g. via executive dysfunction. Fatigue and impaired executive function are commonly linked to disturbed cerebral dopaminergic and noradrenergic neurotransmission. This kind of dysfunction is hard to overcome, even when the major symptoms of depression are alleviated. Interestingly, physical activity has been suggested to improve the dopamine and norepinephrine neurotransmission. Furthermore, the favorable effects may be reciprocal; improved dopamine and norepinephrine transmission in the brain may hypothetically increase the ability and motivation to exercise, since some parts of the brain (e.g. the prefrontal cortex, striatum and cerebellum) that control movement and initiative receive dopaminergic and noradrenergic projections. Based on these findings and assumptions, our hypothesis is that increased dopaminergic and noradrenergic neurotransmission, via intake of a dopamine- and norepinephrine-enhancing agent, improves the compliance with prescribed physical activity in patients with depression and residual fatigue. We also believe that the increased physical activity can prevent relapse into depression, even after interruption of medication. Since increased physical activity also has been shown to improve executive cognitive function, we suggest that executive function should be examined as a secondary outcome together with other possibly related variables such as quality of life, sick leave and BMI.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23127500     DOI: 10.1016/j.mehy.2012.10.007

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  13 in total

1.  Arctigenin enhances swimming endurance of sedentary rats partially by regulation of antioxidant pathways.

Authors:  Ruo-ming Wu; Yan-yan Sun; Ting-ting Zhou; Zhi-yuan Zhu; Jing-jing Zhuang; Xuan Tang; Jing Chen; Li-hong Hu; Xu Shen
Journal:  Acta Pharmacol Sin       Date:  2014-08-25       Impact factor: 6.150

2.  Monoamines and cortisol as potential mediators of the relationship between exercise and depressive symptoms.

Authors:  Lara S F Carneiro; Maria Paula Mota; Maria Augusta Vieira-Coelho; Rita C Alves; António Manuel Fonseca; José Vasconcelos-Raposo
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-08-02       Impact factor: 5.270

3.  Exercise increases mTOR signaling in brain regions involved in cognition and emotional behavior.

Authors:  Brian A Lloyd; Holly S Hake; Takayuki Ishiwata; Caroline E Farmer; Esteban C Loetz; Monika Fleshner; Sondra T Bland; Benjamin N Greenwood
Journal:  Behav Brain Res       Date:  2017-01-24       Impact factor: 3.332

4.  Not All Antidepressants Are Created Equal: Differential Effects of Monoamine Uptake Inhibitors on Effort-Related Choice Behavior.

Authors:  Samantha E Yohn; Samantha L Collins; Hector M Contreras-Mora; Emily L Errante; Margaret A Rowland; Merce Correa; John D Salamone
Journal:  Neuropsychopharmacology       Date:  2015-06-24       Impact factor: 7.853

Review 5.  Pharmacological management of depression in patients with cancer: practical considerations.

Authors:  Riccardo G V Torta; Valentina Ieraci
Journal:  Drugs       Date:  2013-07       Impact factor: 9.546

6.  Effects of lisdexamfetamine and s-citalopram, alone and in combination, on effort-related choice behavior in the rat.

Authors:  Samantha E Yohn; Laura Lopez-Cruz; Peter H Hutson; Merce Correa; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2015-12-23       Impact factor: 4.530

7.  College students with depressive symptoms with and without fatigue: Differences in functioning, suicidality, anxiety, and depressive severity.

Authors:  Maren Nyer; David Mischoulon; Jonathan E Alpert; Daphne J Holt; Charlotte D Brill; Albert Yeung; Paola Pedrelli; Lee Baer; Christina Dording; Ilana Huz; Lauren Fisher; Maurizio Fava; Amy Farabaugh
Journal:  Ann Clin Psychiatry       Date:  2015-05       Impact factor: 1.567

Review 8.  Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology.

Authors:  John D Salamone; Samantha E Yohn; Laura López-Cruz; Noemí San Miguel; Mercè Correa
Journal:  Brain       Date:  2016-05       Impact factor: 13.501

Review 9.  Fighting insomnia and battling lethargy: the yin and yang of palliative care.

Authors:  Mellar P Davis; Harold Goforth
Journal:  Curr Oncol Rep       Date:  2014-04       Impact factor: 5.075

10.  Impact of Fluoxetine on Behavioral Invigoration of Appetitive and Aversively Motivated Responses: Interaction With Dopamine Depletion.

Authors:  Carla Carratalá-Ros; Laura López-Cruz; Andrea Martínez-Verdú; Régulo Olivares-García; John D Salamone; Mercè Correa
Journal:  Front Behav Neurosci       Date:  2021-07-09       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.